Ocugen to Present at Pharma Market Research Conference
January 31 2024 - 8:00AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines,
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-Founder of Ocugen will give the keynote: Future
Innovations in Healthcare: From Dreaming to Community Health at the
Pharma Market Research Conference (PMRC) from February 7-8, 2024 in
Newark, NJ.
“Since its beginnings, biotechnology has become more nuanced and
personalized, and today, gene therapy in particular holds
tremendous promise to cure debilitating conditions,” said Dr.
Musunuri. “I look forward to discussing the rapidly evolving
landscape of gene therapy, including Ocugen’s first-in-class,
gene-agnostic approach to treating blindness diseases.”
PMRC is an impressive industry assembly of market research
executives in pharma, biotech, medical devices, and diagnostics.
The program covers a diverse range of topics and updates on
relevant trends.
Details regarding Dr. Musunuri’s keynote are as follows:
Event: 15th Annual PMRC
Date: Wednesday, February 7, 2024
Location: Newark Liberty International Airport
Marriott
Time: 9-9:30 a.m. ET
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patients’ lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications IR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024